Innate Pharma

Innate Pharma SA (IPHA) will host a conference call on November 13, 2025, to discuss its Q3 2025 business progress. Key executives will present and answer questions. The call will be webcast live and available for replay on the company website. Innate Pharma focuses on developing immunotherapies, including lacutamab, IPH4502, and monalizumab. Investors will focus on clinical trial updates, cash runway, and competitive advantages. Note the presence of forward-looking statements subject to risks detailed in company filings.

Innate Pharma announced its total outstanding shares and voting rights as of July 3, 2025. The company reported 92,183,523 ordinary shares and 6,434, plus 7,581 preferred shares. Total theoretical voting rights stood at 92,962,943, with 92,944,368 exercisable rights. This disclosure complies with French regulatory requirements.